Joulferon

Biotech company Human Genome Sciences, Inc. (Nasdaq: HGSI) reported that a study has showed that a monthly dose of its drug Zalbin to treat hepatitus C is just as effective as the current weekly treatment. Human Genome Sciences is working with Novartis AG (NYSE: NVS) on the drug, with Novartis AG...